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OBJECTIVE: While hepatic resection or local ablative therapy may provide a potentially curative treat-
ment for hepatocellular carcinoma (HCC), more than half of these patients develop recurrent HCC within
5 years after treatment. Thus identification of any therapy which can decrease or delay the incidence of
recurrence will improve the results of treatment. However, no chemopreventive agent has been approved
for HCC.
METHODS: A MEDLINE database, Embase, Cancerlit (National Cancer Institute), and CBM (Chinese
Biomedical Database) search from 1990 to 2009 was performed to identify relevant articles using the 
keywords “hepatocellular carcinoma,” “vitamin analogue,” and “chemoprevention.” Additional papers
were identified by a manual search of the references from the key articles. The fixed effect model was used
for a meta-analysis.
RESULTS: Oral administration of acyclic retinoids (vitamin A analogue), and menatetrenone (vitamin
K2 analogue) have been tested as chemopreventive agents after hepatic resection or local ablative therapy
for HCC. There were one and four randomised, controlled trials (RCTs) which evaluated the efficacy of
polyprenoic acid and menatetrenone, respectively. All studies were conducted in Japan. One RCT showed
the preventive effect of polyprenoic acid in lowering the incidence of HCC recurrence after hepatic resec-
tion or percutaneous ethanol injection, and this effect lasted up to 199 weeks after randomization (or
151 weeks after completion of retinoid administration). Four RCTs evaluated the preventive efficacy of
menatetrenone on HCC recurrence after hepatic resection or local ablative therapy. The results of three
studies, as well as the meta-analysis of all four studies, showed significantly better tumour recurrence-
free survival. The beneficial effect on the overall survival was less definite.
CONCLUSION: There is evidence to suggest that chemopreventive therapy after partial hepatectomy or
local ablative therapy is beneficial in prolonging disease-free survival, but the evidence is less for an effect
on the overall survival. To confirm the beneficial role of vitamin A or K analogues in the chemopreven-
tion of HCC further and larger randomised trials are now required. [Asian J Surg 2010;33(3):120–6]
Key Words: chemoprevention, hepatectomy, hepatocellular carcinoma, vitamin A, vitamin K
Address correspondence and reprint requests to Professor Shu-Qun Cheng, Eastern Hepatobiliary Surgery Hospital, 
The Second Military Medical University, 225 Changhai Road, Shanghai 200438, China.
E-mail: chengshuqun@yahoo.com.cn ● Date of acceptance: 25 August 2010
■ VITAMIN ANALOGUES AND HCC CHEMOPREVENTION ■
ASIAN JOURNAL OF SURGERY VOL 33 • NO 3 • JULY 2010 121
Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world. The number of new cases is esti-
mated to be 500,000–1,000,000 per year.1,2 Eighty per cent
of HCC can be attributed to chronic hepatitis B and C
infection.3 Of the therapies aimed at cure, liver resection
and liver transplantation remain the best choices. Surgical
resection with complete extirpation of the tumour gives the
best chance of a cure for patients with HCC. Unfortunately,
only 10–30% of patients with HCC are amenable to “cura-
tive” surgical resection at the time of diagnosis. Local
ablative therapy may provide a “curative” outcome when
indicated. It has been proved that the survival of local
ablative therapy is similar to that of surgery when the
tumours are small and limited in number.4 In most situa-
tions, liver resection or local ablation remains the available
“curative” therapy for HCC. However, following “curative”
treatment for HCC, 50–90% of postoperative deaths are
the result of recurrent disease. Intrahepatic recurrence is
frequently the only site of recurrence and it occurs in
68–96% of patients.5–7 Thus any therapy which can decrease
or delay the incidence of intrahepatic recurrence will
improve the results of liver resection. However, no neoad-
juvant therapy/adjuvant therapy/chemopreventive ther-
apy has been approved for HCC.8,9
Cancer chemoprevention is defined as the use of specific
natural or synthetic chemical agents to reverse, suppress
or prevent carcinogenic progression to invasive cancer.
The goal of cancer chemoprevention is either to prevent
or reverse the carcinogenic process in the initiation and
promotion phases before the clinical development of cancer,
and/or to delete premalignant or latent malignant clones
from an organ by apoptosis or differentiation induction,
in order to reduce the incidence of disease (and thus, ulti-
mately, to reduce mortality). Over the past decade, several
substances have been investigated as chemopreventive
agents for HCC after “curative” treatments.10–12 Among
these agents, vitamin analogues have been shown to be
promising.12,13 Some studies have reported that vitamin
analogues could reduce HCC recurrence after resection or
local ablation and influence survival. Importantly, any
new strategy must be tested in randomised, controlled trials
(RCTs), including a control group without treatment.
However, the results of these RCTs have been inconsistent.
To review the current position of vitamin analogues in the
chemoprevention of HCC after “curative” treatment, we
performed a systematic review and integrated valid infor-
mation by meta-analysis assessment.
Methods
Search strategy
A MEDLINE database, Embase, Cancerlit (National Cancer
Institute), and CBM (Chinese Biomedical Database)
search from 1990 to 2009 was performed to identify relevant
articles using the keywords “hepatocellular carcinoma,”
“vitamin analogue,” and “chemoprevention.” Additional
papers were identified by a manual search of the refer-
ences from the key articles.
Trial selection criteria
RCTs were included that compared HCC patients who
were or were not given vitamin analogues as a supplement
to curative treatments, including surgical resection, per-
cutaneous ethanol injection, percutaneous thermal abla-
tion and percutaneous radiofrequency ablation. Data
were extracted independently by two authors and discrep-
ancies resolved by consensus. Nonrandomised comparative
studies, RCTs which were unpublished or published in lan-
guages other than English were excluded from the analysis.
Statistical methods
Fixed effect meta-analyses were conducted as described by
Fleiss and Gross14 with the output showing the combined
effect estimate [with 95% confidence interval (CI)] from
each analysis, together with the results of the χ2 test for
homogeneity. Heterogeneity among studies was defined
at a p value less than 0.10. The effect measure of interest
was the odds ratio (OR), which was calculated from
tumour recurrence rate and cumulative survival in each
study. Two independent authors extracted and input the
relevant data into Stata/SE 8.0 for Windows (StataCorp,
College Station, TX, USA) and performed the analysis.
Results
Oral administration of acyclic retinoids (vitamin A ana-
logue), and menatetrenone (vitamin K2 analogue) have
been tested as chemopreventive agents after hepatic resec-
tion or local ablative therapy for HCC. There were one
and four RCTs which evaluated the efficacy of retinoids
and menatetrenone, respectively. All the studies were con-
ducted in Japan.12,13,15–18
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Vitamin A
Retinoids are collectively termed as vitamin A (retinol)
and its derivatives. Muto et al12 randomised patients who
had undergone curative resection or percutaneous ethanol
injection for HCC to receive either polyprenoic acid 
(a synthetic acyclic retinoid) or placebo for 12 months.
After a median follow-up of 38 months, only 12 patients
(27%) treated with polyprenoic acid compared with 22
placebo-treated patients (49%) developed recurrence or
new HCC. The proportion of patients who had second
HCCs was significantly lower in the polyprenoic acid
group than in the placebo group. Survival curves were
estimated for overall survival and disease-free survival
until either the primary tumour progressed or a second
primary tumour appeared, and survival until a second pri-
mary HCC appeared. Compared with placebo, polyprenoic
acid reduced the incidence of treatment failure in all three
categories, but only the change in the incidence of second
primary HCC was significant. Cox proportional-hazards
analysis demonstrated that, as an independent factor,
polyprenoic acid reduced the occurrence of second pri-
mary HCC (adjusted relative risk: 0.31; 95% CI: 0.12–0.78).
Following this RCT, the study group continued to follow-
up the patients by imaging and blood chemical analyses,
and found that the preventive effect of polyprenoic acid
lasted up to 199 weeks after randomisation (or 151 weeks
after completion of retinoid administration).15
Vitamin K
Vitamin K is a fat-soluble vitamin that can be divided into
naturally produced (vitamin K1 and K2) and chemically
synthesized (vitamin K3) forms. Vitamin K inhibits the
proliferation of tumour cells in vitro in decreasing potency
from vitamin K3 to vitamin K1. Four RCTs evaluated the
efficacy of menatetrenone (a vitamin K2 analogue) on
HCC recurrence after hepatic resection or local ablative ther-
apy (Table 113,16–18). Three studies showed significantly
better tumour recurrence-free survival, while all the stud-
ies failed to show any significant effect on overall survival.
Menatetrenone was studied in a pilot RCT by Mizuta
et al13 on 61 patients after curative hepatic resection or
local ablative therapy. The results suggested that menate-
trenone had a suppressive effect on the recurrence of HCC
and a beneficial effect on survival.13 The cumulative recur-
rence rates in the treatment group were 12.5% at 1 year,
39.0% at 2 years, and 64.3% at 3 years; the corresponding
recurrence rates in the control group were 55.2%, 83.2%,
and 91.6%, respectively. The difference was significant.
The 1-year, 2-year and 3-year cumulative overall survival
rates for the treatment group were 100%, 96.6% and 87%,
respectively, while the 1-year, 2-year, and 3-year cumula-
tive survival rates for the control group were 96.4%, 80.9%
and 64%, respectively. The difference was not significant.
In the study of Kakizaki et al,16 60 patients who were diag-
nosed to be free of HCC after radiofrequency ablation
therapy or hepatic resection were randomly assigned to
either the vitamin K2 group (n = 30) or the control group
(n = 30). The results showed that vitamin K2 had a sup-
pressive effect on the recurrence of HCC, but there was no
significant difference in the overall survival rates. The
chemopreventive effects of vitamin K2 may not be sufficient
to prevent death from recurrent HCC. The cumulative
recurrence-free rates in the vitamin K2 group were 92.3%
at 1 year, 48.6% at 2 years and 38.8% at 3 years; those in the
control group were 71.7%, 35.9% and 9.9%, respectively.
The difference was significant. The cumulative overall
survival rates in the vitamin K2 group were 100% at 1 year,
95.0% at 2 years and 77.5% at 3 years, and the corresponding
rates in the control group were 95.8%, 90.2% and 66.4%, res-
pectively. There was no significant difference between the
two groups. In the RCT of Hotta et al,17 recurrence of HCC
occurred in seven patients (33.3%) in the treatment group
(n = 21) and 12 patients (50.0%) in the control group
(n = 24) during mean observation periods of 19.5 and 16.5
months, respectively. Administration of vitamin K2 ana-
logues was not an independent variable for recurrence on
univariate analysis. The cumulative incidence of HCC
recurrence did not differ between the two groups, and the
cumulative overall survival rate tended to be higher in the
treatment group, though this was not significant. In 
the RCT of Yoshiji et al,18 a 4-year follow-up revealed that
combination treatment with a vitamin K2 analogue (men-
atetrenone, 45 mg/day) and an angiotensin converting
enzyme inhibitor (ACE-I) (perindopril, 4 mg/day) for 36–
48 months after curative therapy for HCC markedly in-
hibited the cumulative recurrence of HCC, in association
with suppression of the serum levels of the vascular endo-
thelial growth factor. The cumulative recurrence rates of
HCC in the combined treatment group (n = 25) at 1, 2 and
3 years were 12%, 28%, and 32%, respectively. The correspon-
ding cumulative recurrence rates in the control group
(n = 25) were 24%, 48% and 68%, respectively. The serum lev-
els of lectin-reactive alpha-fetoprotein were also suppressed
almost in parallel with vascular endothelial growth factor.
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These beneficial effects were not observed with single treat-
ment using vitamin K2 or ACE-I. The 1-year, 2-year and 
3-year cumulative recurrence rates in the ACE-I only group
(n = 19) were 16%, 37% and 52%, respectively. In the Vitamin
K2 only (n = 18) group, the 1-year, 2-year and 3-year cumu-
lative recurrence rates were 22%, 44% and 61%, respectively.
No significant differences in overall survival could be ob-
served among all the groups during the follow-up period.
We conducted a fixed effect meta-analysis on these
four studies to assess the effects of vitamin K2 on tumour
recurrence rates and patient survival. Figures 1,13,16–18
213,16–18 and 313,16,18 show the pooled OR of 1-year, 2-year
and 3-year tumour recurrence after curative therapy in the
vitamin K2 treatment patients versus no treatment patients.
Because of the lack of data on the 3-year recurrence in the
OR
0.1 1 10
Mizuta et al13
Combined
Hotta et al17
Kakizaki et al16
Yoshiji et al18
Figure 1. Effect of vitamin K2 on 1-year tumour recurrence after
curative therapy for hepatocellular carcinoma.13,16–18 Fixed effect
model [total odds ratio (OR) = 0.330; 95% confidence interval:
0.164–0.665]. Test for heterogeneity: Q = 5.570 on 3 degrees of
freedom (p=0.134). Test for overall effect: Z=–3.106, p=0.002.
1 10
Combined
Hotta et al17
Kakizaki et al16
Yoshiji et al18
Mizuta et al13
0.1
OR
Figure 2. Effect of vitamin K2 on 2-year tumour recurrence after
curative therapy for hepatocellular carcinoma.13,16–18 Fixed effect
model [total odds ratio (OR) = 0.427; 95% confidence interval:
0.238–0.764]. Test for heterogeneity: Q = 5.418 on 3 degrees of
freedom (p= 0.144). Test for overall effect: Z = –2.867, p= 0.004.
study by Hotta et al,17 the meta-analysis of the 3-year
recurrence included only three studies. Our meta-analysis
by fixed effect model showed that vitamin K2 significantly
decreased HCC recurrence rates at 1, 2 and 3 years after
potentially curative therapy: 1-year tumour recurrence
(OR: 0.330; 95% CI: 0.164–0.665, p = 0.002); 2-year tumour
recurrence (OR: 0.427; 95% CI: 0.238–0.764, p = 0.004); 3-
year tumour recurrence (OR: 0.303; 95% CI: 0.137–0.670,
p = 0.003). The heterogeneity tests were not significant
(Q = 5.570, p = 0.134; Q = 5.418, p = 0.144; Q = 3.125,
p = 0.210, respectively).
Figures 413,16–18 and 513,16–18 show Forrest plots of vita-
min K2 on the 2- and 3-year survivals following curative
therapy using the fixed effect model. As indicated, vita-
min K2 significantly increased the 2-year overall survival
OR
0.1 1
Combined
Kakizaki et al16
Yoshiji et al18
Mizuta et al13
10
Figure 3. Effect of vitamin K2 on 3-year tumour recurrence after
curative therapy for hepatocellular carcinoma.13,16,18 Fixed effect
model [total odds ratio (OR) = 0.303; 95% confidence interval:
0.137–0.672]. Test for heterogeneity: Q = 3.125 on 2 degrees of
freedom (p= 0.210). Test for overall effect: Z = –2.937, p= 0.003.
1 10
Combined
Hotta et al17
Kakizaki et al16
Yoshiji et al18
Mizuta et al13
OR
0.1
Figure 4. Effect of vitamin K2 on 2-year survival after curative
therapy for hepatocellular carcinoma.13,16–18 Fixed effect model
[total odds ratio (OR) = 0.286; 95% confidence interval:
0.089–0.916]. Test for heterogeneity: Q = 1.615 on 3 degrees of
freedom (p= 0.656). Test for overall effect: Z = –2.108, p= 0.035.
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(OR: 0.286; 95% CI: 0.089–0.916, p = 0.035). Although
vitamin K2 had no significant effect on the 3-year survival
(p = 0.055), there was a tendency for the 3-year survival to
be increased (OR: 0.467; 95% CI: 0.214–1.016). The het-
erogeneity tests were not significant (Q = 1.615, p = 0.656;
Q = 1.353, p = 0.508).
Discussion
Recurrences of HCC after “curative” treatment can be dif-
ferentiated into two types, early and late recurrences.7,19,20
Early recurrent HCCs are the result of residual hepatic
tumours presumably left behind after a R0 resection.20,21
In contrast, late recurrent HCCs (otherwise termed de novo
tumour formation) are the results of the underlying pro-
carcinogenic liver diseases or viruses, with the highest risk
in patients with hepatitis B or C.22–24 HCC commonly
arises from chronic viral hepatitis. The livers in these
patients are likely to harbour multiple and independent
clones of premalignant cells. When these clones are fur-
ther exposed to continuous carcinogenic insults, a uni-
centric or multicentric carcinogenesis follows. Intrahepatic
recurrence can either represent de novo tumour formation
in a chronic hepatic liver, or intrahepatic metastasis of a
clonally identical neoplasm. No matter how the recurrence
occurs, it is generally believed that recurrences arise not
because of inadequate resection, but because of pre-existing
microscopic tumour foci that are undetected by imaging
modalities, or because malignant cells have already dis-
seminated during surgical manipulation, or because new
tumours form. To prevent tumour recurrence after curative
treatments, eradication and/or inhibition of such clones
of malignant cells is essential. Thus any therapy which
can decrease or delay the incidence of intrahepatic recur-
rence will improve the results of “curative” treatment.
In vitro, vitamin analogues have been shown to inhibit
experimental hepatocarcinogenesis and induce differenti-
ation and apoptosis of human HCC-derived cell lines.25,26
The chemopreventive effect of retinoids may be conferred
through the deletion of malignant clones before minimal
residual disease becomes clinically detectable after liver
resection.27–29 However, the mechanism of vitamin K
action is not fully understood. Mastumoto et al30 reported
that vitamin K2 inhibited the proliferation of HCC cells
in vitro through cell cycle arrest at the G1 phase and apo-
ptosis. Ozaki et al31 reported that vitamin K2 inhibited the
growth of HCC cells via suppression of cyclin D1 expression
through the IKK/IkappaB/nuclear factor-kappaB path-
way and might therefore be useful for treatment of HCC.
Clinical trials have showed that vitamin analogues had
an influence on recurrence and survival of HCC after cur-
ative treatments. However, none of them could reach a
firm conclusion. Our systematic review found one and
four RCTs which evaluated the efficacy of polyprenoic
acid and menatetrenone, respectively. All the studies were
conducted in Japan. One RCT showed the preventive
effect of polyprenoic acid in reducing the incidence of
HCC recurrence after hepatic resection or percutaneous
ethanol injection, and this effect lasted up to 199 weeks
after randomization (or 151 weeks after completion of
retinoid administration). Four RCTs evaluated the pre-
ventive efficacy of menatetrenone on HCC recurrence
after hepatic resection or local ablative therapy. The results
of three studies, as well as the meta-analysis of all four
studies, showed significantly better tumour recurrence-
free survival. The beneficial effect on the overall survival
is less definite. Thus there is evidence to suggest that
chemopreventive therapy after hepatectomy or local abla-
tive therapy is beneficial to prolong disease-free survival,
but the evidence is less in terms of overall survival. To 
confirm the beneficial role of vitamin A or K analogues in
the chemoprevention of HCC further, larger randomised 
trials are now required.
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